ArticleBMC chemistry2025
QbD-driven RP-HPLC method for the simultaneous analysis of dihydropyridines calcium channel blockers in pharmaceuticals.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Novel Ultra-Performance Liquid Chromatography-Electrospray Ionisation-Tandem Mass Spectrometry Method for Quantification of Imeglimin in Human Plasma: Application to a Bioequivalence Study.Analytical science advances · 2026Article
- Development and validation of a stability-indicating high-performance liquid chromatography method for iomeprol.Scientific reports · 2026Article
- Structural and In silico safety evaluation of asciminib degradation products with a validated stability indicating HPLC method for genotoxic impurity determination.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A rapid, sensitive, and selective reversed-phase high-performance liquid chromatographic (RP-HPLC) method was developed and validated for the simultaneous determination of five dihydropyridines calcium channel blockers, namely: amlodipine (AML), nifedipine (NIF), lercanidipine (LER), nimodipine (NIM) and nitrendipine (NIT) using Quality by Design approaches (QbD). The chromatographic separation was achieved on Luna C8 (100 × 4.6 mm 3 μm) column using an isocratic mobile phase consisting of acetonitrile-methanol - 0.7% triethylamine pH 3.06 (30-35-35) adjusted with ortho phosphoric acid at a flow rate of 1 mL/min with UV detection at 237 nm. The optimized method demonstrated good chromatographic resolution with average retention times of 2.93, 3.98, 4.98, 6.32 and 7.75 min for AML, NIF, LER, NIT and NIM, respectively. The method was validated according to ICH guidelines, showing linearity in the concentration range of 10-50 µg/mL with correlation coefficients (r²) ≥ 0.9989 for all analytes. The method demonstrated high trueness (99.11-100.09%) and precision (RSD < 1.1%). The validated method was successfully applied for the determination of these drugs in their pharmaceutical formulations, with recovery values ranging from 99.57 to 100.07% and without significant interference from excipients. Greenness and practicality evaluations detected using AGREE, MoGAPI, complex MoGAPI, AGSA, CaFRI, BAGI and CACI tools which were, indicating the method's environmental friendliness and excellent practical applicability for routine pharmaceutical quality control analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.